Figure 3.
Overall survival of patients in our dataset treated with nivolumab + ipilimumab combination based upon the number of unfavorable variables for anti‐PD‐1 monotherapy (as described in 13). As the number of unfavorable factors for anti‐PD‐1 outcomes increased, the OS of patients treated with the combination in our dataset generally decreased.